Case-Based Roundtable™

This roundtable series reviews treatments in adult patients with multiple myeloma who have progressed on 1 or more lines of therapy, as discussed by key opinion leaders and participants at virtual live events.

This roundtable series explores therapies after progression on endocrine therapy in patients with estrogen receptor-positive, HER2-negative advanced or metastatic breast cancer who have an ESR1 mutation,as discussed by key opinion leaders and participants at virtual live events.

This roundtable series considers the use of combination treatments in patients with relapsed/refractory multiple myeloma who have received 2 or more lines of therapy, as discussed by key opinion leaders and participants at virtual live events.

This roundtable series discusses immunotherapy treatment used in metastatic or unresectablemelanoma, as discussed by key opinion leaders and participants at virtual live events.

This roundtable series examines systemic therapies and other options approvedin those with steroid-refractorychronic graft-vs-host disease, as discussed by key opinion leaders and participants at virtual live events.

This roundtable series reviews immunotherapy in patients with unresectable hepatocellular carcinoma as first-line treatment, as discussed by key opinion leaders and participants at virtual live events.

This roundtable series evaluates the use of frontline immunotherapy plus chemotherapy in locally advanced or metastatic biliary tract cancer, as discussed by key opinion leaders and participants at virtual live events.

This roundtable series provides context on the growing number of options for patients with non–small cell lung cancer and KRAS G12C mutations, as discussed by key opinion leaders and participants at virtual live events.

This roundtable series assesses later-line treatment of patientswith relapsed/refractory multiple myeloma, as discussed by key opinion leaders and participants at virtual live events.

This roundtable series explores combination treatments for patients with upper gastrointestinal cancer, as discussed by key opinion leaders and participants at virtual live events.

This roundtable series discusses blastic plasmacytoid dendritic cell neoplasms in patients and the ways to identify and provide therapy for this rare disease, as discussed by key opinion leaders and participants at virtual live events.

This roundtable series considers multiple therapies from published clinical trials for patients with relapsed/refractory metastatic clear cell renal cell carcinoma, as discussed by key opinion leaders and participants at virtual live events.

This roundtable series reviews molecular testing in non–small cell lung cancer and potential treatments for patients with EGFR exon 20 mutations, as discussed by key opinion leaders and participants at virtual live events.

This roundtable series provides insights on assessing patients with renal cell carcinoma and how to treat them in the first line based on their risk factors, as discussed by experts in video interviews with Targeted Oncology.

This roundtable series evaluates radioligand therapy in patients with previously treated metastatic castration-resistant prostate cancer with positive prostate-specific membrane antigen, as discussed by participants at virtual live events.

This roundtable series assesses the use of antibody-drug conjugates plus chemoimmunotherapy in patients with relapsed/refractory diffuse large B-cell lymphoma setting, as discussed by participants at virtual live events.

This roundtable series explores tyrosine kinase inhibitor use and other treatments for patients with renal cell carcinoma, as discussed by participants at virtual live events.

This roundtable series discusses when to use chemotherapy and best dosing practices in patients with metastatic castration-resistant prostate cancer after treatment with docetaxel, as discussed by participants at virtual live events.

This roundtable series gauges the use of combination CD19 inhibition and chemotherapy in the previously treated diffuse large B-cell lymphoma setting, as discussed by participants at virtual live events.

This roundtable series considers the use of immunotherapy-based combinations as treatment for non–small cell lung cancer, regardless of the patient’s PD-L1 expression, as discussed by participants at virtual live events.

This roundtable series evaluates the use of therapies such as monoclonal antibodies in advanced non–small cell lung cancer with high PD-L1 expression, as discussed by participants at virtual live events.

This roundtable series reviews the use of treatment targeting EGFR exon 20 insertion mutations in patients with locally advanced or metastatic non–small cell lung cancer, as discussed by participants at virtual live events.

This roundtable series debates using newer JAK inhibitors as therapy for patients with myelofibrosis, considering the efficacy and safety profiles of the drugs, as discussed by participants at virtual live events.

This roundtable series assesses the use of Bruton tyrosine kinase inhibition for patients with previously untreated or relapsed/refractory chronic lymphocytic leukemia, as discussed by participants at virtual live events.

This roundtable series presents physicians' views on how to treat a patient with locally advanced or metastatic HER2-positive gastric cancer, as discussed by participants at virtual live events.

This roundtable series reflects on the management of patients with myeloproliferative neoplasms and JAK mutations, from biopsy and diagnosis to the use of JAK inhibition as treatment, as discussed by participants at virtual live events.

This roundtable series delves into therapies used for limited-stage small cell lung cancer or early-stage non–small cell lung cancer, as discussed by participants at virtual live events.

This roundtable series reviews the use of B-cell maturation antigen–targeted treatments in patients with relapsed/refractory multiple myeloma, as discussed by participants at virtual live events.

This roundtable series considers the use of CDK4/6 inhibitors in patients with hormone receptor–positive, HER2-negative, early-stage breast cancer as discussed by participants at virtual live events.

This roundtable series delves into therapies used for late-stage small and non–small cell lung cancer as discussed by participants at virtual live events.